Jodie Soanes initially put her daughter Lily's tiredness down to growing pains, but when her health deteriorated medics confirmed she had leukaemia - and the 12-year-old soon joined the UK's first pae ...

Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic ...

Advocates and clinicians say that patients are still having trouble getting refills, even though the FDA has lifted REMS for ...

Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...

Philip Bergman, DVM, MS, PhD, DACVIM (Oncology), kicked off the 2025 Fetch Charlotte conference with his keynote address on ...

TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release synd ...

Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in double-expressor lymphoma, with manageable safety, supporting further phase 3 trials.

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

For 35 years, the FDA has placed onerous restrictions on the only drug it has ever approved for treatment-resistant ...